Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot phase II study of oral ITF2357 in refractory or treatment-resistant acute myeloid leukemia not suitable for alternative therapy
2005-005321-63Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- Dec 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in acute myeloid leukemia (AML), sponsored by Italfarmaco. Primary endpoint: Dose-limiting toxicities at each dose level. Started Dec 2008; status: terminated.
02
Drugs
givinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-005321-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005321-63.